Application of p-hydroxyphenylacetic acid in preparation of medicine for preventing and treating inflammatory bowel disease

By discovering that hydroxyphenylacetic acid can inhibit intestinal inflammation and repair intestinal barrier damage in animal models, it solves the problem that the existing technology cannot effectively solve the inflammatory bowel disease, and provides a treatment method with small side effects, with potential clinical Application value.

CN118903085APending Publication Date: 2024-11-08SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410802737.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art cannot effectively solve the fundamental problems of inflammatory bowel disease, especially the increased risk of intestinal barrier damage and cancer, and common drugs have side effects, so it is necessary to develop anti-inflammatory drugs with small and effective side effects.

Method used

Using hydroxyphenylacetic acid to inhibit intestinal inflammation and repair intestinal barrier damage in animal models, it was found that it could reduce DAI intestinal inflammation score and repair intestinal barriers as a prevention and drugs for the treatment of inflammatory bowel disease.

Benefits of technology

Hydroxyphenylacetic acid significantly inhibits intestinal inflammation and repairs intestinal barrier damage in animal models, providing a method to treat inflammatory bowel disease with less side effects, and has potential clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903085A_ABST
    Figure CN118903085A_ABST
Patent Text Reader

Abstract

The invention discloses application of p-hydroxyphenylacetic acid in preparation of drugs for preventing and treating inflammatory bowel diseases. A dextran sodium sulfate induced colitis mouse model discovers that p-hydroxyphenylacetic acid can inhibit intestinal inflammation induced by dextran sodium sulfate, reduce the score of DAI intestinal inflammation and repair intestinal barrier injury, that is, p-hydroxyphenylacetic acid can be used for preventing and treating inflammatory bowel diseases, and can be used for treating inflammatory bowel diseases. The compound can be used for preparing medicines for preventing and treating inflammatory bowel diseases. The invention provides application of p-hydroxyphenylacetic acid in preparation of medicines for preventing and treating inflammatory bowel diseases, which is beneficial to treatment of the inflammatory bowel diseases and development of the medicines for preventing and treating the inflammatory bowel diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of inflammatory bowel disease prevention and treatment, and more specifically, relates to the use of p-hydroxyphenylacetic acid in the preparation of drugs for preventing and treating inflammatory bowel disease. Background Art

[0002] Inflammatory bowel disease (IBD) is a type of idiopathic intestinal inflammatory disease that affects the ileum, rectum, and colon, including Crohn's disease (CD) and ulcerative colitis (UC). Among them, the lesions of ulcerative colitis are located in the rectum and colon, and are mainly manifested as continuous inflammation of the mucosa and submucosa; the lesions of Crohn's disease can affect various parts of the gastrointestinal tract, mainly the terminal ileum and adjacent colon, and are mostly segmental and asymmetric. The incidence of inflammatory bowel disease has a tendency to increase year by year, and it can occur at any age. It has been listed as one of the modern intractable diseases by the World Health Organization.

[0003] At present, the etiology and pathogenesis of inflammatory bowel disease have not been fully clarified. Its main treatment measures are to maintain the remission level of the disease, and it is still unable to solve the fundamental problems of inflammatory bowel disease, especially intestinal barrier damage and intestinal barrier dysfunction. That is, there is no cure for inflammatory bowel disease, and its lifelong recurrence rate is high. As the course of the disease increases, the risk of cancer also increases. Therefore, exploring the pathogenesis of inflammatory bowel disease and finding effective methods to treat inflammatory bowel disease is an important and arduous task.

[0004] In addition, 5-aminosalicylic acid (5-ASA) drugs and glucocorticoids are the first-line treatments for ulcerative colitis and are used for mild to moderate inflammation. Those who are insensitive to the above drugs need to use biological agents and immunosuppressant drugs such as TNF inhibitors. However, long-term use of such drugs can cause side effects such as allergic reactions or liver damage. There is an urgent need to develop new drugs with fewer side effects and that can effectively fight inflammatory bowel disease. Summary of the invention

[0005] The present invention promotes the development of drugs for preventing and treating inflammatory bowel disease and provides the use of p-hydroxyphenylacetic acid in the preparation of drugs for preventing and / or treating inflammatory bowel disease.

[0006] The first object of the present invention is to provide the use of p-hydroxyphenylacetic acid in the preparation of a medicament for preventing and / or treating inflammatory bowel disease.

[0007] The second object of the present invention is to provide the use of p-hydroxyphenylacetic acid in the preparation of a medicament for alleviating intestinal inflammation.

[0008] The third object of the present invention is to provide the use of p-hydroxyphenylacetic acid in the preparation of a medicament for repairing intestinal barrier damage.

[0009] The fourth object of the present invention is to provide a composition for preventing and treating inflammatory bowel disease.

[0010] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0011] Among the animal models used to study the etiology and pathogenesis of inflammatory bowel disease and test the efficacy of newly developed drugs, the colitis model induced by dextran sulfate sodium salt (DSS) is the most widely used. The present invention uses a dextran sulfate sodium salt-induced colitis mouse model to find that p-hydroxyphenylacetic acid can inhibit dextran sulfate sodium salt-induced intestinal inflammation, reduce the mouse DAI intestinal inflammation score, and repair intestinal barrier damage, that is, p-hydroxyphenylacetic acid can be used to prevent and treat inflammatory bowel disease. Therefore, the present invention requests protection for the use of p-hydroxyphenylacetic acid in the preparation of drugs for preventing and / or treating inflammatory bowel disease.

[0012] Specifically, the inflammatory bowel disease includes Crohn's disease and ulcerative colitis.

[0013] Specifically, the p-hydroxyphenylacetic acid can inhibit intestinal inflammation.

[0014] Specifically, the p-hydroxyphenylacetic acid can repair intestinal barrier damage.

[0015] Since p-hydroxyphenylacetic acid can inhibit intestinal inflammation induced by sodium dextran sulfate and reduce the DAI intestinal inflammation score of mice, the present invention also claims the use of p-hydroxyphenylacetic acid in the preparation of a drug for alleviating intestinal inflammation.

[0016] In particular, the use is to alleviate intestinal inflammation in Crohn's disease or ulcerative colitis.

[0017] Since p-hydroxyphenylacetic acid can repair the intestinal barrier damage induced by sodium dextran sulfate, the present invention also requests protection for the use of p-hydroxyphenylacetic acid in the preparation of a drug for repairing intestinal barrier damage.

[0018] Specifically, the application is to repair intestinal barrier damage in Crohn's disease or ulcerative colitis.

[0019] The present invention also provides a composition for preventing and treating inflammatory bowel disease, wherein the composition contains p-hydroxyphenylacetic acid.

[0020] Specifically, the inflammatory bowel disease includes Crohn's disease and ulcerative colitis.

[0021] In addition to p-hydroxyphenylacetic acid, the composition also contains p-hydroxyphenylacetic acid pharmaceutically acceptable excipients.

[0022] The present invention has the following beneficial effects:

[0023] The present invention uses a dextran sulfate sodium salt-induced colitis mouse model to find that p-hydroxyphenylacetic acid can inhibit dextran sulfate sodium salt-induced intestinal inflammation, reduce the mouse DAI intestinal inflammation score, and repair intestinal barrier damage, that is, p-hydroxyphenylacetic acid can be used to prevent and treat inflammatory bowel disease, and can be used to prepare drugs for preventing and treating inflammatory bowel disease.

[0024] The invention provides the use of p-hydroxyphenylacetic acid in the preparation of a drug for preventing and treating inflammatory bowel disease, which is helpful for the treatment of inflammatory bowel disease and the development of drugs for preventing and treating inflammatory bowel disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 The results show the effect of p-hydroxyphenylacetic acid on the body weight of colitis model mice; *** in the figure indicates P < 0.001; *** indicates P < 0.0001.

[0026] Figure 2 These are the results of the effect of p-hydroxyphenylacetic acid on intestinal inflammation in colitis model mice; ** in the figure indicates P < 0.01; *** indicates P < 0.001; *** indicates P < 0.0001.

[0027] Figure 3 The results show the effect of p-hydroxyphenylacetic acid on the colon length of colitis model mice; ** in the figure indicates P < 0.01; *** indicates P < 0.0001.

[0028] Figure 4 These are the results of Western Blot detection of barrier proteins (ZO-1 and Occludin) in the colon tissues of colitis model mice with different treatments.

[0029] Figure 5 The results show the effect of p-hydroxyphenylacetic acid on the expression of barrier protein ZO-1 (Zo1) in colon tissue of colitis model mice; * indicates P < 0.05; ** indicates P < 0.01.

[0030] Figure 6 The results show the effect of p-hydroxyphenylacetic acid on the expression of barrier protein Occludin in colon tissue of colitis model mice; ** in the figure indicates P < 0.01. DETAILED DESCRIPTION

[0031] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0032] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0033] The p-hydroxyphenylacetic acid used in the examples of the present invention was purchased from solarbio, CAS: 156-38-7.

[0034] Example 1 Dextran Sulfate Sodium Salt (DSS)-Induced Colitis Model Mice

[0035] The animals used in constructing the colitis model of the present invention are C57BL / 6 mice, which were purchased from Guangdong Yaokang and raised in the SPF environment of the Experimental Animal Center of the East Campus of Sun Yat-sen University.

[0036] Construction of dextran sulfate sodium salt-induced colitis model mice: 5-week-old C57BL / 6 mice were first adaptively raised for two weeks, and then given normal drinking water for one week, and then the drinking water was replaced with an aqueous solution containing 3% DSS (purchased from Guangzhou Zhuanyan Biotechnology Co., Ltd.; brand: MP; item number: 16011090) for one week to obtain a colitis mouse model.

[0037] Example 2 Effect of p-hydroxyphenylacetic acid on intestinal inflammation in colitis model mice

[0038] In order to explore the in vivo anti-inflammatory activity of p-hydroxyphenylacetic acid, the present invention utilized the classic DSS-induced colitis mouse model and adopted the preventive advance administration method to explore the effect of p-hydroxyphenylacetic acid on intestinal inflammation in colitis mice by observing the weight changes, inflammation scores, pathological morphology and other indicators of the mice during the administration period.

[0039] Thirty-two 5-week-old male C57BL / 6 mice were randomly divided into 4 groups (8 mice in each group) after two weeks of adaptive feeding: normal control group (Control), model group (NC), 5-aminosalicylic acid group (5-ASA) and para-hydroxyphenylacetic acid group (4-PAA); the normal group and the model group were gavaged with PBS for the first 9 days, and the mice in the 5-ASA and 4-PAA groups were gavaged with 5-aminosalicylic acid solution and para-hydroxyphenylacetic acid solution at a dose of 50 mg / kg and 40 mg / kg per day, respectively; after 9 days of gavage, the drinking water of the other three groups except the normal control group was replaced with drinking water containing 3% DSS, and then replaced with normal drinking water after one week. Two days after the end of modeling, the experimental mice were sampled (serum, colon contents, cecum and colon tissues of the mice were collected respectively).

[0040] In addition, during the experiment, the mice were weighed every day, and the DAI scoring system (Disease activity index (DAI) is a comprehensive score based on the percentage of weight loss, stool viscosity and stool bleeding. The total score of the three results is divided by 3 to get the DAI value) was used to score the inflammatory state of the mice. The fecal occult blood test kit used was the Yuanye Biological Fecal Occult Blood Test Kit (Piramisu Hole Method). Refer to the kit instructions, add solution A first, add solution B after 10 seconds, and score according to the color depth change within 3 minutes (light purple 1; purple 2; dark purple 3).

[0041] Effects of p-hydroxyphenylacetic acid on body weight of colitis model mice Figure 1 As shown. Figure 1 The results show that on the 18th day, compared with the normal control group (Control), the weight of mice in the model group (NC) decreased significantly, while the weight of mice in the 4-PAA group (4-PAA) recovered, that is, 4-PAA can alleviate the weight loss of mice caused by DSS, which is the same as the result of the positive drug control group, namely the 5-aminosalicylic acid (5-ASA) group, and its effect is better than 5-aminosalicylic acid.

[0042] Effects of p-hydroxyphenylacetic acid on intestinal inflammation in colitis model mice Figure 2 As shown. Figure 2 The results show that on the 18th day, the DAI inflammatory index of the mice in the model group was significantly increased compared with the normal control group, while p-hydroxyphenylacetic acid could reduce the DAI inflammatory index of the mice, which was the same as the result of the positive drug control group, i.e., the 5-aminosalicylic acid group.

[0043] The results of the effect of p-hydroxyphenylacetic acid on the colon length of colitis model mice are as follows Figure 3 As shown. Figure 3 The results show that compared with the normal control group, the colon length of the mice in the model group was significantly shortened, and p-hydroxyphenylacetic acid can inhibit the shortening of the colon length of mice caused by DSS, which is the same as the result of the positive drug control group, i.e., the 5-aminosalicylic acid group, and the effect is comparable.

[0044] Example 3 Effect of p-hydroxyphenylacetic acid on intestinal barrier damage in mice with colitis

[0045] The present invention uses the colon tissue taken in Example 2 as a sample, and performs Western Blot quantitative detection on the expression of intestinal barrier proteins ZO-1 and Occludin (ZO-1 and Occludin are classic intestinal tight junction proteins, and their levels are closely related to the permeability of the intestinal barrier).

[0046] The specific process is as follows:

[0047] 1. Solution preparation

[0048] (1) Tissue lysis buffer: Prepare an appropriate amount of RIPA lysis buffer and PMSF solution in a ratio of 100:1 (v / v). Add one phosphatase inhibitor tablet per 10 mL and prepare it before use.

[0049] (2) Western Blot electrophoresis buffer: Dissolve 3.03 g Tris, 14.3 g glycine, and 1 g SDS in distilled water and adjust the volume to 1 L;

[0050] (3) Western Blot transfer solution: Dissolve 3.03 g of Tris and 14.3 g of glycine in 800 mL of distilled water, and then add 200 mL of methanol to make the volume 1 L.

[0051] 2. Extraction and Quantification of Protein in Mouse Colon Tissue

[0052] (1) Randomly select colon tissues from 3 mice in each group, weigh 30 mg of colon from each mouse and place in a sterile 2 mL centrifuge tube, place on ice, add 300 μL of prepared tissue lysis buffer to the tube, cut the tissue into small pieces with tissue scissors, and add 2 to 3 grinding magnetic beads;

[0053] (2) Under low temperature conditions, the sample obtained in (1) was placed in a tissue grinder and ground at a frequency of 60 Hz and a time of 60 s to obtain a uniform tissue homogenate;

[0054] (3) Incubate on ice for 30 min, inverting 2 to 3 times to fully lyse the tissue;

[0055] (4) Centrifuge at 14000 g for 10 min at 4°C and transfer to a new centrifuge tube to obtain extracted colon tissue protein;

[0056] (5) using a BCA protein quantification kit, quantify the extracted colon tissue protein according to the kit instructions, and adjust the protein concentration of each sample to the same level;

[0057] (6) Add 1 / 4 volume of Loading Buffer to the adjusted protein solution and boil in a 100°C water bath for 10 min to denature the protein. Aliquot the sample protein and store at -80°C until testing.

[0058] 3. SDS-PAGE electrophoresis

[0059] (1) Gel preparation: Select appropriate separation gel and stacking gel concentrations according to the kit instructions. In this experiment, 8% separation gel and 5% stacking gel were selected and gel preparation was performed according to the instructions.

[0060] (2) Sample loading and electrophoresis: Load the protein samples in the prepared stacking gel in order, and add 4 μL of protein marker on both sides as an indicator; concentrate the samples in the stacking gel at 90 V. After 25 min, when all samples are at the starting point of the separation gel, switch the voltage to 120 V and separate the samples until they are 5 mm from the bottom of the separation gel;

[0061] (3) Transfer: Peel the gel from the glass plate after electrophoresis, cut it appropriately and transfer it to the transfer splint. At the same time, cut a PVDF membrane of the same size as the gel and activate it in methanol. Place the sponge, three-layer filter paper, gel, PVDF membrane, three-layer filter paper, and sponge in the transfer splint in this order. After removing the bubbles, tighten the splint and place it in the transfer solution in an ice water bath for wet transfer at 100V for 55min.

[0062] (4) Blocking: After the transfer is completed, open the transfer splint, take out the PVDF membrane with obvious protein marker imprint, quickly place it in 5% BSA solution, place it on a shaker and gently shake it at room temperature for 2 hours;

[0063] (5) Primary antibody: After gently washing the PVDF membrane in 1× TBST to remove excess BSA solution, cut the PVDF membrane according to the molecular weight of the target protein and internal reference protein and place it in the primary antibody solution diluted in proportion with the primary antibody diluent, and incubate it on a shaker with gentle shaking at 4°C overnight;

[0064] (6) Washing: After the primary antibody is recovered, the membrane is washed with 1× TBST for 10 min each time, for a total of 3 times;

[0065] (7) Secondary antibody: Add the secondary antibody solution diluted in proportion using the secondary antibody diluent, and incubate with gentle shaking on a shaker at room temperature for 1.5 h;

[0066] (8) Washing: After recovering the secondary antibody, rinse with 1× TBST for 10 min each time, for a total of 3 times.

[0067] 4. Protein imaging and image processing

[0068] The luminescent solution was prepared according to the instructions of the eECL chemiluminescence kit. After the strips were infiltrated under light-proof conditions, an appropriate exposure time was selected in a multifunctional imager for exposure imaging. The internal reference protein and target protein after imaging were processed and quantified using ImageJ software.

[0069] Western Blot detection results of barrier proteins (ZO-1 and Occludin) in colon tissues of colitis model mice with different treatments are shown in Figure 2. Figure 4 The results of the effect of p-hydroxyphenylacetic acid on the expression of barrier protein ZO-1 (Zo1) in colon tissue of colitis model mice are shown in Figure 5 The results of the effect of p-hydroxyphenylacetic acid on the expression of barrier protein Occludin in colon tissue of colitis model mice are shown in Figure 6 As shown. Combined Figures 4 to 6 The results show that compared with the normal control group, DSS drinking water will cause a decrease in the expression levels of the intestinal barrier proteins Zo1 and Occludin in mice, indicating that DSS will damage the intestinal barrier of mice, and p-hydroxyphenylacetic acid can alleviate the decrease in the expression levels of Zo1 and Occludin proteins caused by DSS, that is, p-hydroxyphenylacetic acid can repair the intestinal barrier damage caused by DSS, suggesting that p-hydroxyphenylacetic acid can relieve inflammation by repairing the damaged intestinal barrier.

[0070] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Use of p-hydroxyphenylacetic acid in the preparation of a medicament for preventing and / or treating inflammatory bowel disease.

2. The application according to claim 1, characterized in that: The inflammatory bowel diseases include Crohn's disease and ulcerative colitis.

3. The application according to claim 1, characterized in that: The p-hydroxyphenylacetic acid can inhibit intestinal inflammation.

4. The use according to claim 1, characterized in that: The p-hydroxyphenylacetic acid can repair intestinal barrier damage.

5. Application of p-hydroxyphenylacetic acid in the preparation of drugs for relieving intestinal inflammation.

6. The use according to claim 5, characterized in that: The use is to relieve intestinal inflammation in Crohn's disease or ulcerative colitis.

7. Application of p-hydroxyphenylacetic acid in the preparation of drugs for repairing intestinal barrier damage.

8. The use according to claim 7, characterized in that: The application is to repair intestinal barrier damage in Crohn's disease or ulcerative colitis.

9. A composition for preventing and treating inflammatory bowel disease, characterized in that: Contains p-hydroxyphenylacetic acid.

10. The composition according to claim 9, characterized in that The inflammatory bowel diseases include Crohn's disease and ulcerative colitis.